Annovis Bio Inc. has announced the publication of an article in The Scientist detailing the discovery and development of its lead drug candidate buntanetap. The publication comes as the company advances ongoing Phase 3 and extension studies in Alzheimer's disease and Parkinson's disease. According to the company, the article provides historical and scientific context for buntanetap's progression through clinical development.
Current enrollment data shows approximately 70% completion in early Alzheimer's disease trials and 20% enrollment in Parkinson's disease studies. These figures underscore the company's focus on advancing neurodegenerative therapies toward key clinical and regulatory milestones. Buntanetap, formerly known as posiphen, represents an investigational once-daily oral therapy that operates through a specific RNA-targeting mechanism.
The drug candidate inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43. By addressing these underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients suffering from Alzheimer's and Parkinson's diseases. The company's approach targets fundamental pathological processes rather than treating symptoms alone.
Annovis Bio maintains its corporate headquarters in Malvern, Pennsylvania, and trades on the New York Stock Exchange under the symbol ANVS. The company provides regular updates through its official newsroom at https://ibn.fm/ANVS, where investors and interested parties can access the latest information about clinical developments and corporate announcements. Additional company information is available through its primary website at https://www.annovisbio.com.
The publication in The Scientist represents a significant milestone in communicating buntanetap's scientific rationale to the broader research community. As Phase 3 trials continue to enroll patients, the medical community awaits data that could potentially demonstrate the therapy's effectiveness in slowing or halting neurodegenerative disease progression. The development of buntanetap reflects ongoing efforts within the biotechnology sector to address the substantial unmet medical needs in Alzheimer's and Parkinson's diseases, conditions that affect millions of patients worldwide with limited treatment options currently available.
